CNBX Pharmaceuticals Inc. Form 8-K

On March 10, 2026, CNBX Pharmaceuticals Inc. executed a non-convertible Promissory Note with 3i L.P. for $45,000. The note matures on July 1, 2026, and bears simple interest at 5% per annum. The proceeds are intended for immediate working capital purposes and expenditures. The filing also details the terms of the note, including events of default, optional exchange into equity, and redemption options for the holder. It outlines conditions for transfer and the governing law as Delaware. Eyal Barad, Director and CEO, signed the report on March 17, 2026.